Cisatracurium

CHEMBL1201248 Phase 4 Đã phê duyệt Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
929.1 g/mol
LogP
7.9
Phase
4

A nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle relaxation for endotracheal intubation and mechanical ventilation. It undergoes Hofmann elimination, a spontaneous chemical degradation independent of liver or kidney function, making it particularly useful in patients with organ dysfunction. It has minimal histamine-releasing properties compared to atracurium.

Khối lượng phân tử

929,1000 g/mol

LogP

7,90

TPSA

126,00 Ų

Lipinski RO5

Không đạt

Lĩnh vực điều trị

Cơ chế tác dụng

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Cơ chế

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Cấu trúc 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

COc1ccc(C[C@@H]2c3cc(OC)c(OC)cc3CC[N@+]2(C)CCC(=O)OCCCCCOC(=O)CC[N@@+]2(C)CCc3cc(OC)c(OC)cc3[C@H]2Cc2ccc(OC)c(OC)c2)cc1OC

InChI

InChI=1S/C53H72N2O12/c1-54(22-18-38-32-48(62-7)50(64-9)34-40(38)42(54)28-36-14-16-44(58-3)46(30-36)60-5)24-20-52(56)66-26-12-11-13-27-67-53(57)21-25-55(2)23-19-39-33-49(63-8)51(65-10)35-41(39)43(55)29-37-15-17-45(59-4)47(31-37)61-6/h14-17,30-35,42-43H,11-13,18-29H2,1-10H3/q+2/t42-,43-,54-,55-/m1/s1

Molecular Formula

C53H72N2O12+2

HBD / HBA

- / 12

Liên kết có thể quay

26

Nguyên tử nặng

67

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Câu hỏi thường gặp

A nondepolarizing neuromuscular blocking agent that competitively antagonizes acetylcholine at the neuromuscular junction, producing skeletal muscle relaxation for endotracheal intubation and mechanical ventilation. It undergoes Hofmann elimination, a spontaneous chemical degradation independent of liver or kidney function, making it particularly useful in patients with organ dysfunction. It has minimal histamine-releasing properties compared to atracurium.

Blocks neuromuscular transmission at the motor end plate by competing with acetylcholine for nicotinic receptor binding sites, producing skeletal muscle relaxation and paralysis.

Yes, Cisatracurium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201248. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 62887. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Tuyên bố miễn trách y tế

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.